Qlife Holding AB: Qlife reaffirms its strategy and plans to expand the Board with three new members

With approximately 91 percent subscription in the rights issue and a secured credit facility, Qlife has ensured financing for at least the next 12 months. The company is now able to solely focus on advancing its strategy to deliver lab-quality blood testing and AI-powered guidance directly to consumers, initially targeting Women's Health, Rare Diseases, and Home-Hospital care. To drive successful execution and accelerate growth, Qlife proposes to strengthen its Board with three new members who bring valuable expertise in life sciences and commercialization, significantly expanding the company's network and experience.

Provided that the proposal is adopted at the announced EGM:

• Flemming Pedersen will, if elected, assume the role of Chairman of Qlife Holding AB. Currently serving as CFO and Executive Vice President of Better Collective, a digital media group listed on Nasdaq Stockholm and Nasdaq Copenhagen, Flemming brings extensive leadership experience. With over 20 years in the pharmaceutical industry and a track record of executive roles in publicly traded companies, he adds valuable strategic and financial expertise to Qlife. Flemming Pedersen holds 119,061 shares and 99.206 BTAs in Qlife.

• Jørgen Drejer has dedicated his entire career to the pharmaceutical industry, founding or co-founding several biotech companies including Saniona AB and NeuroSearch A/S, where he also served as Chief Scientific Officer. With extensive board experience and business network, he is bringing deep scientific and strategic expertise to Qlife. Jørgen Drejer holds 1,016,313 shares and 583,458 BTAs in Qlife.

• Jacob Glenting is a pharmaceutical commercialization expert with extensive experience in R&D, M&A, strategic partnerships, and market expansion. He is currently a member of ALK Abelló's executive leadership team, where he leads the "Global Strategy and Corporate Development", bringing valuable strategic and business development expertise to Qlife. Jacob Glenting holds no shares in Qlife.

"Having followed Qlife's development efforts for several years, I am truly excited about the company's product offerings that I view as being unique within point-of-care diagnostics. The product offerings can potentially overtake many of the time-consuming central laboratory testing and offer important test results much faster, including applications within home diagnostics. Providing shareholders' approval, I believe we will have a very strong Board that can support Qlife in its continued success." - says Flemming Pedersen, proposed Chairman of the Board of Directors.

"We would be delighted to welcome Flemming, Jørgen, and Jacob to the Board of Qlife. Their proven track record and deep expertise in operating, partnering, and financing biotech companies-from early-stage development to fully operational success-will be invaluable. Together with my management team, assuming they are elected, they will play a crucial role in ensuring the full execution of our strategy." - says Thomas Warthoe, CEO Qlife.